The last flu pandemic came and went in 2009—with lots of advanced hype and much less effect. When the next flu pandemic arrives and its severity is anyone’s guess. Either way, the U.K. has a plan in place.
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that it has begun to ship its portfolio of...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Centers for Disease Control...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that the company's manufacturing facility...
Sanofi is calling on the FDA to change the labels for CSL Limited subsidiary Seqirus’ flu vaccines, which won accelerated approvals but have failed to confirm clinical benefit.
SUMMIT, N.J., Feb. 25, 2022 /PRNewswire/- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) presentation of AUDENZ™ (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
SUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines. These analyses from a comprehensive set of real-world studies will be presented at the global International Society for Influenza and other Respiratory Virus Diseases (ISIRV)-World Health Organization (WHO) Virtual Conference from October 19-21, 2021.
SUMMIT, N.J., Oct. 15, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine, for an expanded age indication for children as young as six months old.4 With this approval, FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine in the U.S., is now indicated for everyone eligible to receive an influenza vaccine in the U.S.
Sanofi, GSK and Seqirus say they're prepared to match last season's record supply of flu shots, warning that this year could be just as precarious.